Thursday, 28 January 2021

Zydus granted Orphan Drug Designation by the USFDA for Saroglitazar in the treatment of patients with Primary Biliary Cholangitis (PBC)

Zydus granted Orphan Drug Designation by the USFDA for Saroglitazar in the treatment of patients with Primary Biliary Cholangitis (PBC) admin Thu, 01/28/2021 - 16:23

source https://www.pharmatutor.org/pharma-news/2021/zydus-granted-orphan-drug-designation-by-the-usfda-for-saroglitazar-in-the-treatment-of-patients-with-primary-biliary-cholangitis

No comments:

Post a Comment

Pharmaceutical Industry and pharma / Life Sciences institute openings 2025

  Intas Pharma Walk in Drive for M.Pharm, B.Pharm | Multiple Posts M.Pharma / B.Pharma. Injectable/Parenteral/Sterile - Aseptic, Manufacturi...